Skip to main content

Table 1

From: Assessing the risk of birth defects associated with atazanavir exposure in pregnancy

  Exposure to any ARV (Jan 1989-Jan 2010) Exposure to ATV (Jun 2003–Jan 2010)
Earliest exposure to ARVs   
First Trimester   
•# of defects/live births 127/4563 8/368
•Prevalence (95% CI) 2.8% (2.3%-3.3%) 2.2% (0.9%-4.2%)
Second/Third Trimester   
•# of defects/live births 158/6184 5/199
•Prevalence (95% CI) 2.6% (2.2%-3.0%) 2.5% (0.8%-5.8%)
Any Trimester   
•# of defects/live births 285/10747 13/567
•Prevalence (95% CI) 2.7% (2.3%-3.0%) 2.3% (1.2%-3.9%)